WO2015008877A1 - 단일공정에 의한 이중층 스캐폴드의 제조방법 및 상기 제조방법에 의해 얻어진 이중층 스캐폴드를 이용한 조직 재생방법 - Google Patents
단일공정에 의한 이중층 스캐폴드의 제조방법 및 상기 제조방법에 의해 얻어진 이중층 스캐폴드를 이용한 조직 재생방법 Download PDFInfo
- Publication number
- WO2015008877A1 WO2015008877A1 PCT/KR2013/006355 KR2013006355W WO2015008877A1 WO 2015008877 A1 WO2015008877 A1 WO 2015008877A1 KR 2013006355 W KR2013006355 W KR 2013006355W WO 2015008877 A1 WO2015008877 A1 WO 2015008877A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- scaffold
- bilayer
- cells
- bilayer scaffold
- gelatin
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/10—Hair or skin implants
- A61F2/105—Skin implants, e.g. artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3821—Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B5/00—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts
- B32B5/22—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts characterised by the presence of two or more layers which are next to each other and are fibrous, filamentary, formed of particles or foamed
- B32B5/32—Layered products characterised by the non- homogeneity or physical structure, i.e. comprising a fibrous, filamentary, particulate or foam layer; Layered products characterised by having a layer differing constitutionally or physically in different parts characterised by the presence of two or more layers which are next to each other and are fibrous, filamentary, formed of particles or foamed at least two layers being foamed and next to each other
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/0061—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof characterized by the use of several polymeric components
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/28—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/30—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by mixing gases into liquid compositions or plastisols, e.g. frothing with air
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/36—After-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/30004—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
- A61F2002/30011—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis differing in porosity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2250/00—Layers arrangement
- B32B2250/22—All layers being foamed
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2201/00—Foams characterised by the foaming process
- C08J2201/02—Foams characterised by the foaming process characterised by mechanical pre- or post-treatments
- C08J2201/026—Crosslinking before of after foaming
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2201/00—Foams characterised by the foaming process
- C08J2201/04—Foams characterised by the foaming process characterised by the elimination of a liquid or solid component, e.g. precipitation, leaching out, evaporation
- C08J2201/048—Elimination of a frozen liquid phase
- C08J2201/0484—Elimination of a frozen liquid phase the liquid phase being aqueous
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2207/00—Foams characterised by their intended use
- C08J2207/10—Medical applications, e.g. biocompatible scaffolds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2301/00—Characterised by the use of cellulose, modified cellulose or cellulose derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2323/00—Characterised by the use of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Derivatives of such polymers
- C08J2323/02—Characterised by the use of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Derivatives of such polymers not modified by chemical after treatment
- C08J2323/04—Homopolymers or copolymers of ethene
- C08J2323/08—Copolymers of ethene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2325/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring; Derivatives of such polymers
- C08J2325/02—Homopolymers or copolymers of hydrocarbons
- C08J2325/04—Homopolymers or copolymers of styrene
- C08J2325/06—Polystyrene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2329/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal, or ketal radical; Hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Derivatives of such polymer
- C08J2329/02—Homopolymers or copolymers of unsaturated alcohols
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2329/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal, or ketal radical; Hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Derivatives of such polymer
- C08J2329/02—Homopolymers or copolymers of unsaturated alcohols
- C08J2329/04—Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2333/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
- C08J2333/02—Homopolymers or copolymers of acids; Metal or ammonium salts thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2339/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Derivatives of such polymers
- C08J2339/04—Homopolymers or copolymers of monomers containing heterocyclic rings having nitrogen as ring member
- C08J2339/06—Homopolymers or copolymers of N-vinyl-pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
- C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2371/00—Characterised by the use of polyethers obtained by reactions forming an ether link in the main chain; Derivatives of such polymers
- C08J2371/02—Polyalkylene oxides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2375/00—Characterised by the use of polyureas or polyurethanes; Derivatives of such polymers
- C08J2375/04—Polyurethanes
- C08J2375/06—Polyurethanes from polyesters
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2379/00—Characterised by the use of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen, or carbon only, not provided for in groups C08J2361/00 - C08J2377/00
- C08J2379/02—Polyamines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2389/00—Characterised by the use of proteins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2489/00—Characterised by the use of proteins; Derivatives thereof
Definitions
- the present invention relates to a method for producing a double layer scaffold by a single process and to a tissue regeneration method using the double layer scaffold obtained by the method.
- Scaffolds refer to physical scaffolds and adhesive substrates made for in vitro culture and transplantation of tissue cells. These scaffolds are used for cell transplantation for human tissue regeneration, and also for mass culture and proliferation of cells. The importance is very high. This is due to the adhesion of the cells at the contact area between the cells and the substrate and the subsequent migration and proliferation of epithelial cells.
- most biologically active cells have a basic step that must be passed in order to survive in contact with substances in or outside the body.
- the first step is cell adhesion.
- the cells preferentially adhere to the substrate, and after adhesion, the metabolism of organelles in the cytoplasm becomes active, and a new site is used to facilitate the proliferation and supply of nutrients. Will move.
- the surface that activates the deposition of cells is the most basic means of doubling cell proliferation.
- the adhesion of these cells to the substrate can be artificially controlled by the components of the substrate.
- Scaffolds are carriers that support scaffolds as they regenerate and grow, that is, the basis of artificial substrates. Recently, scaffolds have been used in mass culture and growth vessels or flasks of cells.
- Korean Patent Laid-Open No. 2004-0016984 relates to a carrier for culturing cells and tissues and a method for culturing, wherein the carrier for culturing cells and tissues that can effectively regenerate a target tissue or organ while suppressing overproliferation of fibroblasts, And cell and tissue culture methods.
- the scaffolds known in the patent are not only excellent in adhesion and physical properties to the substrate to be suitable for mass culture of the cells, but also have many problems in that the manufacturing process is not simple and undesirable.
- a double layer scaffold was manufactured by attaching each polymer scaffold separately and then attaching the double layer scaffold. There is a problem that the process is complicated because it goes through a two-step process of making a thick and individual polymer scaffold.
- the present inventors completed the present invention by confirming that the scaffold obtained by adding a anionic surfactant to a solution in which two polymers are blended to cause phase separation through a high temperature and high speed stirring reaction is a structurally and chemically clear double layer scaffold.
- an object of the present invention is to provide a method for producing a structurally and chemically clear double layer scaffold that is not separated through a simple single process.
- Another object of the present invention is to provide a tissue regeneration method using the bilayer scaffold.
- the present invention comprises the steps of preparing a first polymer aqueous solution; Adding and stirring a second polymer to the first aqueous polymer solution; Adding a surfactant to the stirred reactant to perform high temperature and high speed stirring; Lyophilizing the stirred reactant to obtain a sponge; Dipping the sponge in a crosslinking agent to crosslink it; And it provides a method for producing a double-layer scaffold by a single process comprising the step of lyophilizing the crosslinked reactant again.
- the present invention comprises the steps of preparing a gelatin aqueous solution by stirring at 60 to 70 °C 100 to 300 rpm so that the gelatin is completely dissolved in water; Adding and stirring polyvinyl alcohol (PVA) to the gelatin aqueous solution; Adding sodium dodecyl sulfate to the stirred reactant at a high temperature and high speed at 80 to 120 ° C. to 800 to 2000 rpm; Lyophilizing the stirred reactant to obtain a sponge; Dipping the sponge in a crosslinking agent selected from glutaraldehyde or EDC (Ethyldiethylaminopropylcarbodiimide) to crosslink the sponge; And lyophilizing the crosslinked reactant again.
- PVA polyvinyl alcohol
- the present invention provides a tissue regeneration method comprising culturing cells in a bilayer scaffold according to the preparation method.
- the present invention also provides a composition for tissue regeneration or wound healing comprising the bilayer scaffold.
- the manufacturing method of the present invention unlike the conventional method of manufacturing a double-layer scaffold manufactured in a two-step process by manufacturing and attaching each polymer scaffold separately, it is completely attached through a single process without a separate attachment process
- the double-layer scaffold of the present invention can be prepared, and the cells are cultured in the double-layer scaffold thus prepared and applied to tissue regeneration or wound healing of skin defects, or the co-culture of cartilage cells and bone cells is used to treat tissues such as bone and cartilage. It can be applied to these abutments to promote regeneration of skin tissue lost due to wounds, burns, tumors, and the like.
- FIG. 1 is a flowchart illustrating a manufacturing process of a double layer scaffold according to the present invention
- FIG 3 is a digital image of a bilayer scaffold according to the present invention (A: bilayer scaffold in hydrated state, B: bilayer scaffold in dried state, C: bilayer scaffold dried before crosslinking),
- FIG. 6 shows a bilayer scaffold according to the present invention.
- Micro-CT image A: double layer scaffold, B: gelatin layer
- FIG. 7 is a scanning electron micrograph of cells cultured for one day in a bilayer scaffold according to the present invention.
- 9 and 10 is to treat the wound tissue by treating the bilayer scaffold according to the present invention to examine the effect of tissue regeneration in the wound tissue
- 11 is a result of RT-PCR analysis by cutting the wound tissue treated with the bilayer scaffold.
- the present invention comprises the steps of preparing a first polymer aqueous solution; Adding and stirring a second polymer to the first aqueous polymer solution; Adding a surfactant to the stirred reactant to perform high temperature and high speed stirring; Lyophilizing the stirred reactant to obtain a sponge; Dipping the sponge in a crosslinking agent to crosslink it; And it provides a method for producing a double-layer scaffold by a single process comprising the step of lyophilizing the crosslinked reactant again.
- the first polymer and the second polymer are different polymers , gelatin, Chitosan, elastin, hyaluronic acid, hydroxyapatite, alginate, collagen, cellulose, polyethylene glycol (PEG), polyethylene oxide (PEO), polycaprolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGA), poly [(Lactic-co- (glycolic acid)) (PLGA), poly [(3-hydroxybutyrate) -co- (3-hydroxyvalorate) (PHBV), polydioxanone (PDO), poly [(L Lactide) -co- (caprolactone)], poly (esterurethane) (PEUU), poly [(L-lactide) -co- (D-lactide)], poly [ethylene-co- (vinyl alcohol )] (PVOH), polyacrylic acid (PAA), polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), polyst
- the surfactant may be an anionic surfactant, for example sodium dodecyl sulfate (sds), ammonium lauryl sulfate (als), sodium lauryl ethylene sulfate (sles) ), Linear Alkylbenzene Sulfonate (LAS), Alpha-Olefin Sulfonate (AOS), Alkyl Sulfate (AS), Alkyl Ether Sulfate (AES) and Sodium It may be selected from the group consisting of Alkane Sulfonate (SAS), preferably sodium dodecyl sulfate (SDS).
- sds sodium dodecyl sulfate
- als ammonium lauryl sulfate
- sodium lauryl ethylene sulfate sles
- AOS Alpha-Olefin Sulfonate
- AS Alkyl Sulfate
- AES Alkyl Ether
- the high temperature and high speed stirring is preferably stirred at 800 to 2000 rpm at a temperature of 80 to 120 °C.
- the crosslinking agent may be selected from the group consisting of glutaraldehyde, ethyldiethylaminopropylcarbodiimide (EDC), genepin, and transglutaminase (TG).
- EDC ethyldiethylaminopropylcarbodiimide
- TG transglutaminase
- the present invention comprises the steps of preparing a gelatin aqueous solution by stirring at 100 to 300 rpm at 60 to 70 °C so that the gelatin is completely dissolved in water; Adding and stirring polyvinyl alcohol (PVA) to the gelatin aqueous solution; Adding sodium dodecyl sulfate to the stirred reactant at a high temperature and high speed at 80 to 120 ° C. to 800 to 2000 rpm; Lyophilizing the stirred reactant to obtain a sponge; Dipping the sponge in a crosslinking agent selected from glutaraldehyde or EDC (Ethyldiethylaminopropylcarbodiimide) to crosslink the sponge; And lyophilizing the crosslinked reactant again.
- PVA polyvinyl alcohol
- the present invention provides a tissue regeneration method comprising culturing cells in a bilayer scaffold according to the preparation method.
- the cells may be any one or two or more selected from the group consisting of chondrocytes, bone cells and skin cells, and the cells may be co-cultured by culturing different cells in the upper and lower layers of the bilayer scaffold, respectively. have.
- the present invention also provides a composition for tissue regeneration or wound healing comprising the bilayer scaffold.
- gelatin is used as the first polymer
- polyvinyl alcohol (PVA) is used as the second polymer
- sodium dodecyl sulfate (SDS) is used as the surfactant
- glutaraldehyde is used as the crosslinking agent.
- EDC Ethyldiethylaminopropylcarbodiimide
- preparing a gelatin aqueous solution by stirring at 100 to 300 rpm at 60 to 70 °C so that the gelatin is completely dissolved in water; Adding and stirring polyvinyl alcohol (PVA) to the gelatin aqueous solution; Adding sodium dodecyl sulfate to the stirred reactant at a high temperature and high speed at 80 to 120 ° C. to 800 to 2000 rpm; Lyophilizing the stirred reaction at -80 ° C.
- PVA polyvinyl alcohol
- a sponge Dipping the sponge in a crosslinking agent selected from glutaraldehyde or EDC (Ethyldiethylaminopropylcarbodiimide) to crosslink the sponge; And lyophilizing the crosslinked reactant at -80 ° C to prepare a bilayer scaffold.
- a crosslinking agent selected from glutaraldehyde or EDC (Ethyldiethylaminopropylcarbodiimide)
- gelatin which is a natural polymer
- the gelatin aqueous solution is preferably 1 to 99% by weight gelatin aqueous solution, preferably 2.5% by weight gelatin aqueous solution. If the gelatin content in the aqueous solution of gelatin is out of the above range, it may cause a problem of not visually confirming that the layer separation occurs.
- Polyvinyl alcohol (PVA) is added to the gelatin aqueous solution and stirred to prepare a polymer blend solution such that PVA is contained in an amount of 1 to 99% by weight, preferably 12.5% by weight. If the PVA content is out of the above range, it may cause a problem of not visually confirming that delamination occurs.
- SDS Sodium dodecyl sulfate
- the stirred reaction was lyophilized at -80 ° C. for 24 to 48 hours to obtain a sponge, and the sponge was immersed in a crosslinking agent selected from glutaraldehyde or EDC (Ethyldiethylaminopropylcarbodiimide) and crosslinked.
- the crosslinking agent is an aqueous solution containing 0.1 to 1% by weight of a crosslinking agent such as glutaraldehyde or EDC (Ethyldiethylaminopropylcarbodiimide), and crosslinking for 3 to 24 hours. If the content of the crosslinking agent is out of the above range, the crosslinking reaction may not occur to decompose in solution, or may cause problems in cell culture due to the residue of the crosslinking agent which does not occur.
- the crosslinked reactant is lyophilized again at -80 ° C to prepare a bilayer scaffold.
- FIG. 2 shows a bilayer scaffold having a porous gelatin layer on the left side and a high density PVA layer on the right side.
- FIGS. 4 and 5 show FT-IR microscopic images of the bilayer scaffold and the graphs of the gelatin layer and the PVA layer, respectively, by comparing the prepared gelatin scaffold or the PVA scaffold with a control. As a result, the gelatin layer and the PVA layer were confirmed.
- A double-layer scaffold
- B gelatin layer
- the red portion is a porous gelatin layer
- the gray portion is a high density PVA layer; Indicates.
- ECM extracellular matrix
- the tissue began to fill up from the skin subcutaneously one day after the treatment of the bilayer scaffold according to the present invention.
- the tissue is integrated into the bilayer scaffold, and after 10 days, the tissue is being regenerated.
- the gelatin layer is decomposed and the scaffold begins to detach itself, but does not completely detach.
- the gelatin layer of the bilayer scaffold is almost completely decomposed, and desorption occurs by itself, and the wound is also almost completely regenerated.
- the control group maintains about 80% of the wound after 5 days.
- tissue regeneration is performed without contraction of the wound, and the contraction of the wound is a different concept from tissue regeneration and healing, and the wound site becomes hard and dense through the contraction of the wound, thereby becoming a general scar tissue.
- FIG. 11 is a result of treatment of the bilayer scaffold according to the present invention at the site of injury and RT-PCR analysis by cutting the tissue of the part having the bilayer scaffold after one day, and on the first day, an extracellular matrix (ECM) protein.
- ECM extracellular matrix
- ITGA3 is expressed when the integrin reacts with, the expression is not expressed on day 5, IL-8 is not expressed on day 5 was confirmed that the bilayer scaffold according to the present invention does not cause an immune response.
- CD55 which inhibits the formation of COL16A1
- a fibrils that form collagen which is a major component of ECM, VEGF, and C5a, which is associated with blood coagulation, is increased.
- the bilayer scaffold according to the present invention can be widely used as a material for drug, cell, protein and growth factor delivery or artificial skin in tissue engineering, medicine, pharmacy and materials science, and especially for tissue regeneration or wound healing. It can be usefully used as.
- the cells can be cultured in a bilayer scaffold according to the above production method and used for tissue regeneration or wound healing.
- the cells may be any one or two or more selected from the group consisting of chondrocytes, bone cells and skin cells, and the cells may be co-cultured by culturing different cells in the upper and lower layers of the bilayer scaffold. It may be.
- the bilayer scaffold according to the present invention can be applied to skin defects.
- the cells are cultured in a bottom layer scaffold made of natural polymer and used as a tissue regeneration layer.
- the drug is loaded into the top layer scaffold made of synthetic polymer and bacteria from outside during tissue regeneration. It can stop infection.
- the natural polymer scaffold is biodegraded and removed as tissue regeneration proceeds, and the synthetic polymer scaffold is removed when tissue regeneration is completed.
- the bilayer scaffold according to the present invention may be co-cultured with two kinds of cells and applied to a portion where tissues are in contact with each other, such as bone and cartilage, to help regeneration at the same time. That is, culturing chondrocytes in a bottom layer scaffold made of a natural polymer, culturing bone cells in a top layer scaffold made of a synthetic polymer, and then the double layer scaffold in a part where the tissue is in contact. Apply to help tissue regeneration.
- Gelatin aqueous solution was prepared at 2.5% by weight and stirred at 80 rpm at 300 rpm. After the gelatin was completely dissolved, polyvinyl alcohol (PVA) was added to 10 wt% and stirred. Sodium dodecyl sulfate was added to 0.2% by weight, and the mixture was stirred at 95 ° C. and 900 rpm at high temperature and high speed. The stirred solution was poured into a petri dish and lyophilized at ⁇ 80 ° C. for at least 24 hours to obtain a sponge. The sponge was immersed in an aqueous solution containing 0.5 wt% of glutaraldehyde and crosslinked for at least 12 hours. Again, lyophilization at ⁇ 80 ° C. yielded a bilayer scaffold.
- PVA polyvinyl alcohol
- Sodium dodecyl sulfate was added to 0.2% by weight, and the mixture was stirred at 95 ° C. and 900 rpm at high temperature and high
- the SEM images of the double-layer scaffold thus prepared with the field emission scanning electron microscope (FE-SEM), S-4100, HITACHI, LTD are as shown in Figure 2, the field emission scanning electron microscope (FE-SEM), S- Digital images taken with 4100, HITACHI, LTD are shown in FIG. 3.
- the double-layer scaffold is completely integrally attached to confirm that it is a safe double-layer scaffold without separation.
- the bilayer scaffolds thus prepared were analyzed by scanning liquid microscope with liquid nitrogen in a microscope FTIR Spectro photometer (Spectrum 100, PerkinElmer, USA) / imaging systems (Spotlight 200, PerkinElmer, USA) chamber. PVA scaffolds were analyzed as a control.
- the bilayer scaffold thus prepared was analyzed using a SKYSCAN1172 (Skyscan, German) to analyze the micro-CT image, wherein the monochromatic beam 40 kV, the sample and detector distance 45.14 mm, exposure time 147 ms, pixel size
- the analysis was carried out by fixing to 4.84362 ⁇ m.
- the micro-CT image of the double-layer scaffold according to the present invention as shown in Figure 6 (A: double-layer scaffold, B: gelatin layer), the red portion is a porous gelatin layer, the gray portion is a high density PVA layer Indicated.
- a 7 mm wound was made using a biopsy punch, and a 7 mm size bilayer scaffold of the same size was raised and banded with the gelatin layer in contact with the wound area.
- a 7 mm size bilayer scaffold of the same size was raised and banded with the gelatin layer in contact with the wound area.
- for sterilization of the scaffold soaked in 20, 40, 60, 80, 100% of ethanol for 1 hour and finally soaked in 70% ethanol for 24 hours, and then soaked in PBS buffer for 3 hours at room temperature Used.
- the control group was left open with the wound, and the test group was made of the wound and then covered with the double layer scaffold according to the present invention.
- the tissue when looking at the photograph one day after the double layer scaffold treatment, the tissue began to rise from the subcutaneous of the skin, while in the control group more than 90% of the wound remains, while in the experimental group about 80% wound
- the size of the site was reduced, and 5 days later, when looking at the photograph, the tissue was inserted into the bilayer scaffold according to the present invention, and the size of the wound site was also reduced to about 80% in the control group, while the experimental group was less than 40% of the initial size.
- RT-PCR analysis was performed by treating the damaged layer of the bilayer scaffold according to the present invention in the same manner as in Experimental Example 2 and cutting the tissue of the portion having the double layer scaffold after one day.
- RT-PCR analysis conditions were as follows: 5 minutes at 94 ° C. (initial denaturation), 30 seconds at 94 ° C. 30 cycles (denature), 30 seconds at 55-60 ° C. (annealing), and 72 ° C. depending on the melting point of the primer. 75 cycles (final extension) for 1 minute (extended) and finally 10 minutes at 72 ° C.
- the PCR product thus obtained was analyzed by gel electrophoresis.
- the primer set used is as follows.
- ITGA3 which is expressed when integrins react with ECM (extracellular matrix) protein, is expressed on day 1, and its expression does not appear on day 5, and IL-8 is not expressed on day 5. It was confirmed that the bilayer scaffold according to the present invention did not cause an immune response.
- the expression of CD55 which inhibits the production of the fibril COL16A1, the vascular endothelial growth factor VEGF, and the inflammatory substance C5a associated with blood coagulation, which forms collagen, which is a major component of ECM, was increased.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Cell Biology (AREA)
- Materials Engineering (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
증폭대상 | 정방향 프라이머 | 역방항 프라이머 |
COL16A1 | cattggtattggcattgcag (서열 1) | tcccaacggagtctttcatc (서열 2) |
ITGA3 | tattcctccgaaccagcatc (서열 3) | ctcttcatctccgccttctg (서열 4) |
VEGF | ATCTGCATGGTGATGTTGGA (서열 5) | GGGCAGAATCATCACGAAGT (서열 6) |
CD55 | TCCACCCGTCTTGTTTGTCC (서열 7) | CTCAGAGACCGACTTGGACC (서열 8) |
GAPDH | CGGAGTCAACGGATTTGGTCGTATTGG (서열 9) | GCTCCTGGAAGATGGTGATGGGATTTCC (서열 10) |
Claims (11)
- 제1 고분자 수용액을 준비하는 단계;상기 제1 고분자 수용액에 제2 고분자를 첨가하여 교반하는 단계;상기 교반한 반응물에 계면활성제를 첨가하여 고온고속 교반하는 단계;상기 교반한 반응물을 동결건조시켜 스폰지를 얻는 단계;상기 스폰지를 가교제에 담구어 가교시키는 단계; 및상기 가교된 반응물을 재차 동결건조시키는 단계를 포함하는 단일공정에 의한 이중층 스캐폴드의 제조방법.
- 청구항 1에 있어서, 상기 제1 고분자 및 제2 고분자는 서로 다른 고분자로서, 젤라틴, 키토산, 엘라스틴, 히알루론산, 하이드록시아파타이트, 알지네이트, 콜라겐, 셀룰로오스, 폴리에틸렌글리콜(PEG), 폴리에틸렌옥사이드(PEO), 폴리카프로락톤(PCL), 폴리락트산(PLA), 폴리글리콜산(PGA), 폴리[(락틱-co-(글리콜산))(PLGA), 폴리[(3-하이드록시부티레이트)-co-(3-하이드록시발러레이트)(PHBV), 폴리다이옥산온(PDO), 폴리[(L-락타이드)-co-(카프로락톤)], 폴리(에스테르우레탄)(PEUU), 폴리[(L-락타이드)-co-(D-락타이드)], 폴리[에틸렌-co-(비닐알코올)](PVOH), 폴리아크릴산(PAA), 폴리비닐알코올(PVA), 폴리비닐피롤리돈(PVP), 폴리스티렌(PS) 및 폴리아닐린(PAN)으로 이루어진 군에서 선택된 것을 특징으로 하는 이중층 스캐폴드의 제조방법.
- 청구항 1에 있어서, 상기 제1 고분자는 젤라틴이고, 제2 고분자는 폴리비닐알코올(PVA)인 것을 특징으로 하는 이중층 스캐폴드의 제조방법.
- 청구항 1에 있어서, 상기 계면활성제는 소듐 도데실 설페이트(Sodium Dodecyl Sulfate; SDS), 암모늄 라우릴 설페이트(Ammonium Lauryl Sulfate; ALS), 소듐 라우릴 에틸렌 설페이트(Sodium Lauryl Ethylene Sulfate; SLES), 선형 알킬벤젠 설포네이트(Linear Alkylbenzene Sulfonate; LAS), 알파-올레핀 설포네이트(-Olefin Sulfonate; AOS), 알킬 설페이트(Alkyl Sulfate; AS), 알킬 에테르 설페이트(Alkyl Ether Sulfate; AES) 및 소듐 알칸 설포네이트(Sodium Alkane Sulfonate; SAS)로 이루어진 군에서 선택된 것을 특징으로 하는 이중층 스캐폴드의 제조방법.
- 청구항 1에 있어서, 상기 고온고속 교반은 80 내지 120℃의 온도에서 800 내지 2000 rpm으로 교반하는 것을 특징으로 하는 이중층 스캐폴드의 제조방법.
- 청구항 1에 있어서, 상기 가교제는 글루타르알데히드(Glutaraldehyde), 에틸디에틸아미노프로필카보디이미드(Ethyldiethylaminopropylcarbodiimide; EDC), 제니핀(genepin), 및 트랜스글루타미나제(transglutaminase; TG)로 이루어진 군에서 선택된 것을 특징으로 하는 이중층 스캐폴드의 제조방법.
- 청구항 1에 있어서, 젤라틴이 물에 완전히 용해되도록 60 내지 70℃에서 100 내지 300 rpm으로 교반하여 젤라틴 수용액을 준비하는 단계; 상기 젤라틴 수용액에 폴리비닐알콜(PVA)을 첨가하여 교반하는 단계; 상기 교반한 반응물에 소듐 도데실 설페이트(Sodium dodecyl sulfate)를 첨가하여 80 내지 120℃에서 800 내지 2000 rpm으로 하여 고온고속 교반하는 단계; 상기 교반한 반응물을 동결건조시켜 스폰지를 얻는 단계; 상기 스폰지를 글루타르알데히드(Glutaraldehyde) 또는 EDC(Ethyldiethylaminopropylcarbodiimide) 중에서 선택된 가교제에 담구어 가교시키는 단계; 및 상기 가교된 반응물을 재차 동결건조시키는 단계를 포함하는 것을 특징으로 하는 이중층 스캐폴드의 제조방법.
- 청구항 1 내지 청구항 7 중 어느 한 항의 제조방법에 따른 이중층 스캐폴드에 세포를 배양하는 것을 특징으로 하는 조직 재생방법.
- 청구항 8에 있어서, 상기 세포는 연골세포, 뼈세포 및 피부세포로 이루어진 군에서 선택된 어느 하나 또는 둘 이상인 것을 특징으로 하는 조직 재생방법.
- 청구항 8에 있어서, 상기 세포는 이중층 스캐폴드의 상층과 하층에 각각 다른 세포를 배양하여 공배양하는 것을 특징으로 하는 조직 재생방법.
- 청구항 1 내지 청구항 7 중 어느 한 항의 제조방법에 따른 이중층 스캐폴드를 포함하는 조직재생 또는 상처치유용 조성물.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2013/006355 WO2015008877A1 (ko) | 2013-07-16 | 2013-07-16 | 단일공정에 의한 이중층 스캐폴드의 제조방법 및 상기 제조방법에 의해 얻어진 이중층 스캐폴드를 이용한 조직 재생방법 |
CN201380079610.9A CN105611952B (zh) | 2013-07-16 | 2013-07-16 | 通过单步过程制备双层支架的方法以及利用由该制备方法获得的双层支架进行组织再生的方法 |
US14/905,827 US10864300B2 (en) | 2013-07-16 | 2013-07-16 | Method for preparing bilayer scaffold through single process and method for regenerating tissue using bilayer scaffold obtained by preparing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2013/006355 WO2015008877A1 (ko) | 2013-07-16 | 2013-07-16 | 단일공정에 의한 이중층 스캐폴드의 제조방법 및 상기 제조방법에 의해 얻어진 이중층 스캐폴드를 이용한 조직 재생방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015008877A1 true WO2015008877A1 (ko) | 2015-01-22 |
Family
ID=52346313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/006355 WO2015008877A1 (ko) | 2013-07-16 | 2013-07-16 | 단일공정에 의한 이중층 스캐폴드의 제조방법 및 상기 제조방법에 의해 얻어진 이중층 스캐폴드를 이용한 조직 재생방법 |
Country Status (3)
Country | Link |
---|---|
US (1) | US10864300B2 (ko) |
CN (1) | CN105611952B (ko) |
WO (1) | WO2015008877A1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105412974A (zh) * | 2015-11-27 | 2016-03-23 | 广州市朴道联信生物科技有限公司 | 一种双层结构角膜修复材料的制备方法 |
CN105920680A (zh) * | 2016-06-03 | 2016-09-07 | 昆明理工大学 | 一种软组织工程多孔支架及其制备方法 |
US10863371B2 (en) | 2018-04-25 | 2020-12-08 | Rohde & Schwarz Gmbh & Co. Kg | Measurement arrangement and measurement method |
CN112370571A (zh) * | 2020-11-26 | 2021-02-19 | 同济大学 | 治疗颌面部骨缺损的骨组织工程支架材料及其合成方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108310449A (zh) * | 2018-03-12 | 2018-07-24 | 常州市蒽盗钟情生物科技有限公司 | 一种用于止血的明胶海绵的制备方法 |
US11998654B2 (en) | 2018-07-12 | 2024-06-04 | Bard Shannon Limited | Securing implants and medical devices |
CN111249534B (zh) * | 2020-01-16 | 2021-06-15 | 中国人民解放军总医院 | 可用于促进创面组织同步修复再生的生物活性支架及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008017858A2 (en) * | 2006-08-11 | 2008-02-14 | Cambridge Enterprise Limited | Biomaterial |
WO2010084481A1 (en) * | 2009-01-23 | 2010-07-29 | Royal College Of Surgeons In Ireland | Layered scaffold suitable for osteochondral repair |
KR20100104219A (ko) * | 2009-03-17 | 2010-09-29 | 주식회사 동성바이오폴 | 연골 재생을 위한 다공성 연골-골 복합 지지체 및 이의 제조 방법 |
KR20110097662A (ko) * | 2010-02-24 | 2011-08-31 | 주식회사 티이바이오스 | 관절연골 재생용 지지체 및 이의 제조방법 |
WO2012134024A1 (ko) * | 2011-03-31 | 2012-10-04 | 인제대학교 산학협력단 | 이중막 구조의 튜브형 다공성 스캐폴드와 줄기 세포를 이용한 인공 혈관의 제조 방법 및 이에 의하여 제조된 인공 혈관 |
KR20130124797A (ko) * | 2012-05-07 | 2013-11-15 | 영남대학교 산학협력단 | 단일공정에 의한 이중층 스캐폴드의 제조방법 및 상기 제조방법에 의해 얻어진 이중층 스캐폴드를 이용한 조직 재생방법 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003006635A1 (fr) | 2001-07-13 | 2003-01-23 | Mebiol Inc. | Support pour culture de cellules et de tissus et procede de culture |
US20070185585A1 (en) * | 2004-03-09 | 2007-08-09 | Brat Bracy | Implant Scaffold Combined With Autologous Tissue, Allogenic Tissue, Cultured Tissue, or combinations Thereof |
EP2209890A4 (en) * | 2006-12-13 | 2011-11-02 | Tgr Biosciences Pty Ltd | STIMULATION OF PRODUCTION OF EXTRACELLULAR MEDIA WITH FIBROBLAST CELLS AND / OR STIMULATION OF MIGRATION OF FIBROBLAST CELLS IN A BIOLOGICAL SYSTEM |
CN101249275B (zh) * | 2008-01-10 | 2011-06-29 | 中国人民解放军第二军医大学 | 一种可隔离海水的创面敷料及其制备方法 |
CN101254313B (zh) * | 2008-04-03 | 2011-05-11 | 厦门大学 | 双层胶原-壳聚糖海绵支架的制备方法 |
US20100049322A1 (en) * | 2008-08-19 | 2010-02-25 | Warsaw Orthopedic, Inc. | Osteochondral repair implants and methods |
CN101874751B (zh) * | 2009-04-30 | 2013-07-10 | 复旦大学 | 一种多层多孔支架及其制备方法 |
US9683216B2 (en) | 2011-03-31 | 2017-06-20 | Inje University Industry-Academic Cooperation Foundation | Method for preparation of artificial blood vessel using tube-type porous biodegradable scaffold having a double-layered structure and stem cell, and artificial blood vessel made by the same |
-
2013
- 2013-07-16 US US14/905,827 patent/US10864300B2/en active Active
- 2013-07-16 CN CN201380079610.9A patent/CN105611952B/zh not_active Expired - Fee Related
- 2013-07-16 WO PCT/KR2013/006355 patent/WO2015008877A1/ko active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008017858A2 (en) * | 2006-08-11 | 2008-02-14 | Cambridge Enterprise Limited | Biomaterial |
WO2010084481A1 (en) * | 2009-01-23 | 2010-07-29 | Royal College Of Surgeons In Ireland | Layered scaffold suitable for osteochondral repair |
KR20100104219A (ko) * | 2009-03-17 | 2010-09-29 | 주식회사 동성바이오폴 | 연골 재생을 위한 다공성 연골-골 복합 지지체 및 이의 제조 방법 |
KR20110097662A (ko) * | 2010-02-24 | 2011-08-31 | 주식회사 티이바이오스 | 관절연골 재생용 지지체 및 이의 제조방법 |
WO2012134024A1 (ko) * | 2011-03-31 | 2012-10-04 | 인제대학교 산학협력단 | 이중막 구조의 튜브형 다공성 스캐폴드와 줄기 세포를 이용한 인공 혈관의 제조 방법 및 이에 의하여 제조된 인공 혈관 |
KR20130124797A (ko) * | 2012-05-07 | 2013-11-15 | 영남대학교 산학협력단 | 단일공정에 의한 이중층 스캐폴드의 제조방법 및 상기 제조방법에 의해 얻어진 이중층 스캐폴드를 이용한 조직 재생방법 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105412974A (zh) * | 2015-11-27 | 2016-03-23 | 广州市朴道联信生物科技有限公司 | 一种双层结构角膜修复材料的制备方法 |
CN105920680A (zh) * | 2016-06-03 | 2016-09-07 | 昆明理工大学 | 一种软组织工程多孔支架及其制备方法 |
CN105920680B (zh) * | 2016-06-03 | 2018-11-27 | 昆明理工大学 | 一种软组织工程多孔支架及其制备方法 |
US10863371B2 (en) | 2018-04-25 | 2020-12-08 | Rohde & Schwarz Gmbh & Co. Kg | Measurement arrangement and measurement method |
CN112370571A (zh) * | 2020-11-26 | 2021-02-19 | 同济大学 | 治疗颌面部骨缺损的骨组织工程支架材料及其合成方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105611952A (zh) | 2016-05-25 |
US10864300B2 (en) | 2020-12-15 |
US20160287754A1 (en) | 2016-10-06 |
CN105611952B (zh) | 2018-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015008877A1 (ko) | 단일공정에 의한 이중층 스캐폴드의 제조방법 및 상기 제조방법에 의해 얻어진 이중층 스캐폴드를 이용한 조직 재생방법 | |
Bonvallet et al. | Microporous dermal-mimetic electrospun scaffolds pre-seeded with fibroblasts promote tissue regeneration in full-thickness skin wounds | |
KR101333381B1 (ko) | 단일공정에 의한 이중층 스캐폴드의 제조방법 및 상기 제조방법에 의해 얻어진 이중층 스캐폴드를 이용한 조직 재생방법 | |
Zhou et al. | Fabrication and characterization of collagen/PVA dual-layer membranes for periodontal bone regeneration | |
KR101684790B1 (ko) | 비표면적이 다른 이중층 구조를 가지는 경조직 재생용 다공성 멤브레인 및 그 제조방법 | |
WO2020204230A1 (ko) | 나노섬유 및 하이드로젤의 복합체 및 이를 포함하는 조직 재생용 스캐폴드 | |
Wang et al. | Multilayer scaffold of electrospun PLA–PCL–collagen nanofibers as a dural substitute | |
Garcia Cruz et al. | Differentiation of mesenchymal stem cells in chitosan scaffolds with double micro and macroporosity | |
Boffito et al. | Surface functionalization of polyurethane scaffolds mimicking the myocardial microenvironment to support cardiac primitive cells | |
Park et al. | Human turbinate mesenchymal stromal cell sheets with bellows graft for rapid tracheal epithelial regeneration | |
WO2016153179A1 (ko) | 3차원 프린팅용 조성물, 이의 제조방법, 및 이를 사용한 3차원 구조체의 제조방법 | |
Liu et al. | Regulation of ERK1/2 and SMAD2/3 pathways by using multi-layered electrospun PCL–amnion nanofibrous membranes for the prevention of post-surgical tendon adhesion | |
EP1835949A2 (en) | Tissue engineering devices for the repair and regeneration of tissue | |
US20190060517A1 (en) | Scaffold for cardiac patch | |
Zhao et al. | Toward improved wound dressings: Effects of polydopamine-decorated poly (lactic-co-glycolic acid) electrospinning incorporating basic fibroblast growth factor and ponericin G1 | |
US20160129044A1 (en) | Use of mesothelial cells in tissue bioengineering and artificial tissues | |
Ayala et al. | Engineered composite fascia for stem cell therapy in tissue repair applications | |
JP2023535979A (ja) | 繊維複合材料 | |
Li et al. | Highly interconnected inverse opal extracellular matrix scaffolds enhance stem cell therapy in limb ischemia | |
Nishiwaki et al. | In situ transplantation of adipose tissue‐derived stem cells organized on porous polymer nanosheets for murine skin defects | |
Nie et al. | 3D bio-printed endometrial construct restores the full-thickness morphology and fertility of injured uterine endometrium | |
Ku et al. | Chitosan/poly (l‐lactic acid) multilayered membrane for guided tissue regeneration | |
Lesage et al. | Minimal modulation of the host immune response to SIS matrix implants by mesenchymal stem cells from the amniotic fluid | |
CN1210071C (zh) | 生物活性骨组织诱导再生膜及其制备方法 | |
WO2016163612A1 (ko) | 세포 외 기질이 코팅된 골 재생용 지지체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13889459 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14905827 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13889459 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13889459 Country of ref document: EP Kind code of ref document: A1 |